医学
特应性皮炎
硫唑嘌呤
甲氨蝶呤
不利影响
临床试验
发病机制
杜皮鲁玛
白细胞介素
毒性
免疫学
细胞因子
皮肤病科
药理学
疾病
内科学
作者
Matthew C Matsunaga,Paul S. Yamauchi
出处
期刊:PubMed
日期:2016-08-01
被引量:23
摘要
Atopic dermatitis (AD) is a chronic, prevalent, multi-factorial condition that affects infants, children, and adults. Beyond topical therapy, a variety of systemic agents such as steroids, methotrexate, cyclosporine, azathioprine, mycophenoloic acid, and other agents are utilized to treat moderate to severe AD. However, these agents are associated with potential long term adverse events and organ toxicity. There is an unmet need for a safer, long-term systemic agent to adequately control moderate to severe AD. The role of the Th2 cytokines, IL-4 and IL-13, in AD has led to the development of biologic agents to treat AD. The aim of this article is to review the role of IL-4 and IL-13 in the pathogenesis of AD and discuss some of the clinical trial data that target and inhibit IL-4 and IL-13 in positively altering the course and outcome of AD.
J Drugs Dermatol. 2016;15(8):925-929.
科研通智能强力驱动
Strongly Powered by AbleSci AI